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Background
Vaccination with live attenuated SIV confers potent
protection against wild-type SIV challenge in the SIV/
macaque model of HIV. Although safety concerns pre-
clude direct application of this vaccine approach in
humans, a clearer understanding of the mechanistic pro-
cesses at play may lead to better HIV vaccines. A novel
live attenuated SIVmac239Δnef vaccine (SIVrtTA),
dependent on doxycycline (dox) administration for repli-
cation, has been evaluated for its ability to protect in
vivo against independent homologous and heterologous
pathogenic wild-type (wt) SIV challenges, and the role
of vaccine persistence assessed. We recently demon-
strated immunophenotyping of SIVrtTA vaccinees prior
to wt challenge drives global polarisation of a T cell
memory phenotype, particularly in the CD4 population,
toward an effector memory response.
Materials and methods
Initially, two groups of six Indian rhesus macaques (RM)
were vaccinated with SIVrtTA with an oral doxycycline
dosing regime for 6 months. In Group A, doxycycline
was stopped 8 weeks before homologous wild-type SIV-
mac239 challenge but continued in Group B. Separately,
Mauritian cynomolgus macaques (CM) were vaccinated
with SIVrtTA in three groups (Grp A; 20 wks dox-on,
Grp B; 3 wks dox-on, 17 wks dox-off; Grp C; 3 wks
dox-on) and challenged with the heterologous wild-type
SIVsmE660. Kinetics of vaccine virus replication and
superinfection resistance outcomes were determined by
sensitive and specific molecular and virological assays
and detailed immunological studies performed.
Results
Following wild-type challenge with either SIVmac239 or
SIVsmE660, all SIVrtTA vaccinees exhibited significantly
lower levels of breakthrough virus which in 2/8 SIVrtTA
vaccinees challenged with SIVmac239 and 10/18 chal-
lenged with SIVsmE660 were protected from detectable
wt virus. While the kinetics of vaccine virus replication
differed between species, in Indian RM enhanced con-
trol of wild-type virus was correlated with a transitory
shoulder of sustained plasma viral RNA load in the per-
iod up to 100 days post-vaccine delivery. On the day of
challenge, a high frequency of circulating CD8+ TEM
was associated with protection but was not necessarily
essential. In Mauritian CM there was a clear correlation
between persistence of the vaccine virus and protection
with 6/6 protected against detectable SIVsmE660 infec-
tion after 20 weeks vaccination (dox ‘on’), with 1/6 pro-
tected after 3 weeks vaccination (dox ‘on’) and 3/6 dox
‘on’ for 3 weeks followed by 17 weeks dox ‘off’.
Conclusions
Together, these data suggest a maturation of protection
with longer periods of vaccination is beneficial, even
when the vaccine-virus is apparently ‘switched-off’. Since
the genetics and antigenic relatedness of vaccine and
challenge virus does not appear to predict the outcome
of these vaccine studies, the kinetics and relative persis-
tence of vaccine virus replication in contributing to
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adaptive and innate immune responses are being evalu-
ated. The outcome of these studies will inform rational
HIV/AIDS vaccine design
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